Form 4: Cardiff Oncology CFO James Levine Reports Stock Option Grant

James Levine, CFO of Cardiff Oncology, reports the acquisition of stock options.

Summary

• James E. Levine, the Chief Financial Officer of Cardiff Oncology, Inc., filed a Form 4 with the SEC.
• The filing reports a transaction that occurred on March 11, 2025.
• Levine acquired 332,621 stock options with an exercise price of $3.58.
• These options vest over time, with 25% vesting on March 11, 2026, and the remainder vesting in 36 equal monthly installments thereafter, contingent upon continued service.
• Following the reported transaction, Levine beneficially owns 1,295,117 shares of common stock directly.

Sentiment

Score: 6

Explanation: The document is a neutral regulatory filing. The granting of stock options is generally viewed as a positive incentive for management, but the filing itself doesn't convey strong positive or negative sentiment.

Positives

• The granting of stock options to the CFO aligns his interests with those of the shareholders.
• The vesting schedule incentivizes continued service and commitment from the CFO.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with shareholder value.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive incentive for the CFO to drive company performance.
• Employees may see the grant as a sign of confidence in the company's future.

Key Dates

Keywords

Form 4, Cardiff Oncology, Stock Options, Beneficial Ownership, James Levine, CFO